CKI 7 dihydrochloride: Transforming Casein Kinase 1 Inhibition in Research

Principle Overview: Targeting CK1 for Signaling Pathway Dissection

CKI 7 dihydrochloride is a potent, selective Casein kinase 1 (CK1) inhibitor, designed for high-fidelity modulation of serine/threonine kinase activity in biochemical and cellular models. By competitively inhibiting the ATP-binding site of CK1, CKI 7 dihydrochloride facilitates precise manipulation of phosphorylation events that are central to processes like Wnt/β-catenin signaling, circadian rhythm regulation, and cellular DNA repair (product_spec). Its exceptional purity (98%) and proven cell permeability make it an indispensable tool for researchers seeking to untangle the complexities of CK1-mediated pathways, especially in the context of cancer biology and neurobiology (complement).

Key Innovation from the Reference Study

The recent publication by Luo et al. illuminates the pivotal role of kinase signaling in non-small cell lung cancer (NSCLC) metastasis. The study demonstrates that mitogen-activated protein kinase 10 (MAPK10) phosphorylates keratin 16 (KRT16), triggering RNF213-mediated ubiquitination and proteasomal degradation of KRT16. This phosphorylation-dependent mechanism suppresses the migration and invasion of NSCLC cells, positioning the MAPK10/KRT16/RNF213 axis as a promising therapeutic and prognostic target (paper). For researchers, these findings translate into actionable strategies: employing CKI 7 dihydrochloride to dissect the upstream or parallel modulation of CK1 in Wnt signaling, cell motility, and apoptosis assays, with the potential to model or counterbalance MAPK-related effects in cancer cells.

Step-by-Step Workflow: Applied Use-Cases for CKI 7 Dihydrochloride

Integrating CKI 7 dihydrochloride into experimental workflows enables precise inhibition of CK1 and downstream effectors. Here’s a stepwise guide for leveraging this compound in key research applications:

• Wnt/β-catenin Pathway Inhibition: CKI 7 dihydrochloride provides a direct means to interrogate CK1’s role in the phosphorylation of β-catenin and related substrates. For optimal results, pre-treat cells with the compound before Wnt ligand stimulation to capture early CK1-dependent phosphorylation events (extension).
• Apoptosis Assays Using CK1 Inhibitors: CKI 7 dihydrochloride can be integrated into cell viability or apoptosis protocols to probe CK1’s involvement in cell survival pathways. Pair with caspase activity readouts or Annexin V/PI staining for quantitative assessment (complement).
• Cancer Biology Research: In NSCLC models, use CKI 7 dihydrochloride to explore how CK1 inhibition modulates cytoskeletal protein phosphorylation, migration, and invasion—providing a functional counterpoint to MAPK10-centric studies (paper).
• Circadian Rhythm Regulation Studies: CKI 7 dihydrochloride is uniquely suited for dissecting CK1-driven phosphorylation of clock proteins (e.g., PER, CRY) in cell-based or biochemical assays, facilitating time-course analysis of downstream gene expression (complement).

Protocol Parameters

• Western blot or in vitro kinase assay | 10–50 μM CKI 7 dihydrochloride | Suitable for dose-response assessment of CK1 activity in cell lysates or purified systems | Literature-backed range captures both partial and near-complete kinase inhibition | product_spec
• Cell-based signaling assay | 5–20 μM, 1–6 hours pre-treatment | Optimal for inhibiting CK1 before Wnt or circadian pathway stimulation in adherent cells | Minimizes off-target effects and maximizes specificity for early pathway events | workflow_recommendation
• Storage and solubility | ≤17.93 mg/ml in DMSO at -20°C, use freshly prepared | Ensures compound stability and assay reproducibility; avoid long-term storage of solutions | Prevents degradation and preserves inhibitor potency | product_spec

Advanced Applications and Comparative Advantages

CKI 7 dihydrochloride stands out for its high selectivity, enabling clear attribution of observed effects to CK1 inhibition. Unlike broad-spectrum kinase inhibitors, this compound minimizes confounding off-target interactions, thus enhancing the interpretability of mechanistic experiments (complement). In cancer biology research, CKI 7 dihydrochloride allows for the precise modeling of CK1-dependent cytoskeletal and signaling changes relevant to metastasis, as highlighted by the MAPK10/KRT16 study (paper). Similarly, in circadian rhythm regulation studies, its application sharpens the resolution of temporal phosphorylation events, aiding in the dissection of clock protein networks (extension).

Troubleshooting and Optimization Tips

• Compound Solubility: Owing to its moderate solubility in DMSO (<17.93 mg/ml), prepare concentrated stocks in DMSO and dilute immediately before use to prevent precipitation; avoid freeze-thaw cycles (product_spec).
• Assay Timing: For dynamic signaling events (e.g., Wnt pathway activation), time pre-treatments carefully (1–6 hours) and include untreated and vehicle controls to distinguish CK1-specific effects from broader kinase inhibition (workflow_recommendation).
• Concentration Ranging: Start with a concentration gradient (e.g., 5, 10, 20, 50 μM) to empirically determine the minimum effective dose for your assay, as cell type and endpoint may influence sensitivity (complement).
• CK1 Pathway Readouts: Use orthogonal assays—such as β-catenin stabilization, phospho-specific antibodies, or luciferase reporters—to validate CK1 inhibition and minimize false negatives or positives due to pathway redundancy (workflow_recommendation).

Interlinking Related Resources

The article "CKI 7 Dihydrochloride: Advancing CK1 Inhibition in Oncology" complements the present discussion by providing a strategic overview of CKI 7 dihydrochloride’s role in translational cancer research, particularly its contextualization within NSCLC metastasis models. Meanwhile, "CKI 7 dihydrochloride: Precision Casein Kinase 1 Inhibitor" extends the mechanistic insights to neurobiological and circadian applications, highlighting the breadth of CK1’s influence in cellular signaling. The recent publication on CKI 7 dihydrochloride’s selectivity further underscores its value in pathway-specific experimental designs. Collectively, these resources build a comprehensive foundation for leveraging CKI 7 dihydrochloride in both fundamental and applied bioscience.

Future Outlook: Implications from Current Evidence

Building on the evidence that kinase-mediated modulation of cytoskeletal proteins like KRT16 can suppress metastatic behavior in NSCLC, CKI 7 dihydrochloride offers a scalable approach to probe CK1’s contribution in similar pathways (paper). As profiling of kinase-substrate relationships becomes more sophisticated, this inhibitor will remain an essential tool for both validating new targets and dissecting complex signaling crosstalk. With growing interest in precision medicine, the specificity and reproducibility provided by APExBIO’s CKI 7 dihydrochloride will be instrumental in refining cellular models that inform future therapeutic strategies.

For more information or to order, visit the CKI 7 dihydrochloride product page at APExBIO.